Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TWST

Twist Bioscience Corporation

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for TWST. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.21

Twist Bioscience Corporation (NASDAQ: TWST) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 13:41 UTC.

What Twist Bioscience Corporation does

Twist Bioscience develops and sells a DNA synthesis platform that writes synthetic DNA directly on silicon chips, enabling the manufacture of synthetic genes and related products at lower cost and higher speed than traditional methods. The company serves more than customers across healthcare, chemicals/materials, academic research, and food/agriculture sectors through two main product lines: synthetic biology tools used in drug discovery and genetic research, and next-generation sequencing tools that help prepare patient samples for analysis.

Summarized from Twist Bioscience Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.21

Revenue, margins & earnings

FY2021: net loss $152M on revenue $132M$132MFY2021FY2022: net loss $218M on revenue $204M$204MFY2022FY2023: net loss $205M on revenue $245M$245MFY2023FY2024: net loss $209M on revenue $313M$313MFY2024FY2025: net loss $78M on revenue $377M$377MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-13
  • 2026-10-13Chief Financial OfficerSale-2,462$384.8K
  • 2026-10-07Chief Executive OfficerSale-290$59.4K
  • 2026-10-07Chief Executive OfficerSale-481$96.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Twist Bioscience Corporation do?

Twist Bioscience develops and sells a DNA synthesis platform that writes synthetic DNA directly on silicon chips, enabling the manufacture of synthetic genes and related products at lower cost and higher speed than traditional methods.

When did TWST last file with the SEC?

Twist Bioscience Corporation's most recent SEC filing on record is a 10-Q filed 2026-05-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:41 UTC. This page is also available as JSON at /api/data?ticker=TWST and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TWST and 5,000+ tickers.

Create a free account — keep TWST
For your agent
GET /api/data?ticker=TWST

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt